BioSpace News Archive

Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system diseases, today announces the dosing of its first patient in its Phase 2b clinical trial of the mGluR5 inhibitor NOE-101 in trigeminal neuralgia (TN).

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), today announced that it received notice from the U.S. Food and Drug Administration (FDA) that the company’s New Drug Application (NDA) resubmission for its apomorphine infusion device (SPN-830).

Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the Digital Oral Presentation of new data at the 17th Congress of European Crohn’s and Colitis Organisation (ECCO) supporting the ongoing MORF-057 development program in inflammatory bowel disease (IBD).

Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “we” or “us”), today announced that it has initiated Good Manufacturing Practice (“GMP”) manufacturing of IMX-120, a biologic for inflammatory bowel disease (“IBD”). ImmixBio anticipates filing an IND for IMX-120 in 2023, representing a significant milestone on ImmixBio’s path to clinical trials for IMX-120 in inflammatory bowel disease.

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer, today announced it has entered into a definitive agreement to acquire Cancer Prevention Pharmaceuticals, Inc. (“CPP”), a private clinical stage company developing therapeutics to reduce the risk and recurrence of cancer and rare diseases, for a combination of stock and future milestone payments.

BostonGene today announced its publication, “Conserved pan-cancer microenvironment subtypes predict response to immunotherapy,” has been selected by Cancer Cell as one of ten research articles that represent cutting-edge areas of cancer research and oncology in 2021.

Code Biotherapeutics, Inc. (Code Bio), a biotechnology company pioneering targeted non-viral delivery of genetic medicines, today announced a collaboration and option agreement with Takeda to leverage Code Bio’s proprietary targeted 3DNA® non-viral genetic medicine delivery platform to design and develop gene therapies for rare disease indications.

Element Biosciences, Inc. today announced a key technical milestone using the Roche KAPA HyperPlus and KAPA EvoPlus library preparation and target enrichment kits in microbial whole genome, human whole genome, and human whole exome sequencing applications.

The annual report highlights the significant efforts the company has made in advancing healthcare globally, increasing the diversity and engagement of its workforce, and reducing its global environmental footprint.

AbbVie today announced that it has submitted a supplemental New Drug Application (sNDA) for cariprazine (VRAYLAR®) to the U.S. Food and Drug Administration (FDA) for the adjunctive treatment of major depressive disorder (MDD) in patients who are receiving ongoing antidepressant therapy.